Results 11 to 20 of about 3,595 (167)

Dalbavancin to Complete a Prolonged Antibiotic Course for Persistent <i>Bacillus cereus</i> Bacteremia: A Case Report and Literature Review. [PDF]

Case Rep Infect Dis
Bacillus cereus is a Gram‐positive, rod‐shaped facultative anaerobe commonly associated with gastrointestinal infections. Although typically regarded as a blood culture contaminant, B.
Yetukuri J, Choi J, Darkow A.
europepmc   +3 more sources

Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting. [PDF]

Infection
Dalbavancin is a long-acting lipoglycopeptide with Gram-positive activity, licensed for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), although off-licence use is increasingly prevalent.
Darlow CA, Parsons J, Lucy D, Li A, Ratcliffe L, Todd S, Wong N.   +6 more
europepmc   +2 more sources

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? [PDF]

Infect Dis Ther
The clinical landscape of Gram-positive infections has been reshaped with the introduction of long-acting lipoglycopeptides, particularly dalbavancin and oritavancin.
Hussein M, Barclay J, Baker M, Wu Y, Thombare VJ, Patil N, Murthy AB, Sharma R, Rao GG, Blaskovich MAT, Li J, Velkov T.   +11 more
europepmc   +2 more sources

Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO). [PDF]

J Bone Jt Infect
Introduction: Long-term dalbavancin use is increasingly adopted off-label for osteoarticular infections (OAIs), but data on administration timing and long-term effects beyond 12 weeks are scarce.
Mariani C, Passerini M, Galli L, Covizzi A, Colaneri M, Offer M, Faenzi M, Merli S, Landonio S, Fusi M, Dolci A, Gori A, Cattaneo D.   +12 more
europepmc   +2 more sources

Bridging to Transplant: TDM-guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease With Deep-seeded Inoperable Abscesses Over 11 Months. [PDF]

Open Forum Infect Dis
Therapeutic drug monitoring facilitated the successful outpatient use of low-dosage dalbavancin for treating inoperable staphylococcal abscesses in a patient with chronic granulomatous disease.
Banz M, Hagel S, Sörgel F, Kinzig M, Farker K, Pletz MW, Kentouche K.   +6 more
europepmc   +2 more sources

Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study. [PDF]

Pathogens
Bone and joint infections remain therapeutic challenges, usually requiring prolonged intravenous therapy and hospitalization. Dalbavancin, a long-acting lipoglycopeptide, offers a simplified alternative.
Petropoulou C, Ioannou P, Eleftherakis G, Papazisi S, Davoulos C, Drosou E, Spiliopoulou A, Tsiata E, Paliogianni F, Kofteridis D, Marangos M, Assimakopoulos SF.   +11 more
europepmc   +2 more sources

Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital. [PDF]

Clin Drug Investig
Acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), and osteomyelitis often require extended antimicrobial therapy courses. Dalbavancin’s long half-life allows outpatient or emergency department (ED) management of
Raja K, Chen B, Chandra O, Patel M, Philips M.   +4 more
europepmc   +2 more sources

Real-World Use of Dalbavancin in a United States Tertiary Referral Center. [PDF]

Cureus
Introduction Outpatient management of serious bacterial infections can be difficult particularly in situations where outpatient parenteral antibiotic therapy may be difficult due to patient-specific factors such as history of medical non-compliance ...
Polega J, Bhugra M, Vanderhorst D, de Sanctis J, Chang A, Hassouna H.   +5 more
europepmc   +2 more sources

Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study. [PDF]

Ther Drug Monit
Background: Implant-associated spinal infections (IASI) pose challenges for outpatient management due to the need for frequent intravenous antibiotic administration. Dalbavancin has a prolonged half-life and is a practical alternative. Methods: Two cases
Houwen JPA, Hakkers CS, Schweitzer VA, Bognàr T, Toren-Wielema ML, Touw DJ, de Vries Schultink AHM.   +6 more
europepmc   +2 more sources

Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study. [PDF]

J Clin Med
Background: Data on antibiotic treatment for diabetic foot osteomyelitis are limited. This study aims to describe the real-world effectiveness and safety of dalbavancin in treating deep diabetic foot infections.
Núñez LM, Benito AR, Bereciartua E, Morata L, Escudero-Sánchez R, Nadal JS, Gómez-Junyent J, Botrán AS, García AMA, Del Toro López MD, Ruiz-Cabrera D, Andrino JMR, Alidrous F, Torío-Salvador M, Verdejo MÁ, Velasco Arribas M.   +15 more
europepmc   +2 more sources